語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Poor Quality Pharmaceuticals in Glob...
~
Kimura, Satoru.
Poor Quality Pharmaceuticals in Global Public Health
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Poor Quality Pharmaceuticals in Global Public Health/ by Satoru Kimura, Yasuhide Nakamura.
作者:
Kimura, Satoru.
其他作者:
Nakamura, Yasuhide.
面頁冊數:
XXIII, 191 p. 22 illus., 15 illus. in color.online resource. :
Contained By:
Springer Nature eBook
標題:
Development and Health. -
電子資源:
https://doi.org/10.1007/978-981-15-2089-1
ISBN:
9789811520891
Poor Quality Pharmaceuticals in Global Public Health
Kimura, Satoru.
Poor Quality Pharmaceuticals in Global Public Health
[electronic resource] /by Satoru Kimura, Yasuhide Nakamura. - 1st ed. 2020. - XXIII, 191 p. 22 illus., 15 illus. in color.online resource. - Trust, Interdisciplinary Perspectives,52509-7679 ;. - Trust, Interdisciplinary Perspectives,2.
Preface -- Global aspect of imitated products and poor quality pharmaceuticals -- Problem awareness among the WHO and other major international organizations -- Precedent academic works and media reports -- Bias or misleading by the WHO? -- Standardization and its advantages in globalization -- Global events associated with modern medicines -- WHO medicines policy in public health -- IMPACT and conflicts of international society -- Case study I: Access to medicines in Indonesia -- Case study II: Supply side of medicines in India -- Case study III: Health-care service market in Japan -- An interpretation and lessons to learn.
This book aims to clarify the global aspects of poor quality pharmaceuticals, generic products in particular, becoming complicated through the process of IMPACT (International Medical Products Anti-Counterfeiting Taskforce) organized by the initiative of the World Health Organization (WHO) in 2006. The findings from this book provide a long-term perspective to policymakers. This book discusses from the following points: industrial standardization, healthcare market accessibility, motivation on supply side, WHO medicines policy and intellectual property rights. Standardization regulates the quality and enabled the generic medicines spreading to developing/emerging countries through technology transfer. However, quality is a part of cost and reflected to price. When a healthcare service market is divided according to wealth gap, compliance to standardization for quality on supply side is divided accordingly. Thus, poor quality pharmaceuticals are prevalent worldwide. Generic pharmaceuticals are essential resources in public health. The WHO has been involved in the dispute around the intellectual property rights under its intention to promote the new drug development for neglected diseases. Global pandemic of AIDs is a critical factor to accelerate the confusion. This created feelings of distrust among developing/emerging countries against developed countries if the WHO was in favour of developed countries. In addition to that, an easy and optimistic start of IMPACT stirred up conflicts of interests in the international community. The problem of poor quality pharmaceuticals became more complicated through the conflicts on intellectual property rights; patented drugs to generic drugs. A key for quality generic products is the formation of a single healthcare service market where good motivation on supply side together with fair competitiveness with patented pharmaceuticals and equitable access to services (both for the rich and the poor) are ensured. Political commitment to investment and regulatory infrastructure for the market is crucial.
ISBN: 9789811520891
Standard No.: 10.1007/978-981-15-2089-1doiSubjects--Topical Terms:
1143010
Development and Health.
LC Class. No.: RA1-1270
Dewey Class. No.: 613
Poor Quality Pharmaceuticals in Global Public Health
LDR
:04143nam a22004215i 4500
001
1027826
003
DE-He213
005
20200704081635.0
007
cr nn 008mamaa
008
210318s2020 si | s |||| 0|eng d
020
$a
9789811520891
$9
978-981-15-2089-1
024
7
$a
10.1007/978-981-15-2089-1
$2
doi
035
$a
978-981-15-2089-1
050
4
$a
RA1-1270
072
7
$a
MBN
$2
bicssc
072
7
$a
MED078000
$2
bisacsh
072
7
$a
MBN
$2
thema
082
0 4
$a
613
$2
23
082
0 4
$a
614
$2
23
100
1
$a
Kimura, Satoru.
$e
author.
$4
aut
$4
http://id.loc.gov/vocabulary/relators/aut
$3
1324276
245
1 0
$a
Poor Quality Pharmaceuticals in Global Public Health
$h
[electronic resource] /
$c
by Satoru Kimura, Yasuhide Nakamura.
250
$a
1st ed. 2020.
264
1
$a
Singapore :
$b
Springer Singapore :
$b
Imprint: Springer,
$c
2020.
300
$a
XXIII, 191 p. 22 illus., 15 illus. in color.
$b
online resource.
336
$a
text
$b
txt
$2
rdacontent
337
$a
computer
$b
c
$2
rdamedia
338
$a
online resource
$b
cr
$2
rdacarrier
347
$a
text file
$b
PDF
$2
rda
490
1
$a
Trust, Interdisciplinary Perspectives,
$x
2509-7679 ;
$v
5
505
0
$a
Preface -- Global aspect of imitated products and poor quality pharmaceuticals -- Problem awareness among the WHO and other major international organizations -- Precedent academic works and media reports -- Bias or misleading by the WHO? -- Standardization and its advantages in globalization -- Global events associated with modern medicines -- WHO medicines policy in public health -- IMPACT and conflicts of international society -- Case study I: Access to medicines in Indonesia -- Case study II: Supply side of medicines in India -- Case study III: Health-care service market in Japan -- An interpretation and lessons to learn.
520
$a
This book aims to clarify the global aspects of poor quality pharmaceuticals, generic products in particular, becoming complicated through the process of IMPACT (International Medical Products Anti-Counterfeiting Taskforce) organized by the initiative of the World Health Organization (WHO) in 2006. The findings from this book provide a long-term perspective to policymakers. This book discusses from the following points: industrial standardization, healthcare market accessibility, motivation on supply side, WHO medicines policy and intellectual property rights. Standardization regulates the quality and enabled the generic medicines spreading to developing/emerging countries through technology transfer. However, quality is a part of cost and reflected to price. When a healthcare service market is divided according to wealth gap, compliance to standardization for quality on supply side is divided accordingly. Thus, poor quality pharmaceuticals are prevalent worldwide. Generic pharmaceuticals are essential resources in public health. The WHO has been involved in the dispute around the intellectual property rights under its intention to promote the new drug development for neglected diseases. Global pandemic of AIDs is a critical factor to accelerate the confusion. This created feelings of distrust among developing/emerging countries against developed countries if the WHO was in favour of developed countries. In addition to that, an easy and optimistic start of IMPACT stirred up conflicts of interests in the international community. The problem of poor quality pharmaceuticals became more complicated through the conflicts on intellectual property rights; patented drugs to generic drugs. A key for quality generic products is the formation of a single healthcare service market where good motivation on supply side together with fair competitiveness with patented pharmaceuticals and equitable access to services (both for the rich and the poor) are ensured. Political commitment to investment and regulatory infrastructure for the market is crucial.
650
2 4
$a
Development and Health.
$3
1143010
650
2 4
$a
Corporate Social Responsibility.
$3
1085768
650
2 4
$a
Medical Sociology.
$3
1105129
650
1 4
$a
Public Health.
$3
592982
650
0
$a
Economic development.
$3
555228
650
0
$a
Social responsibility of business.
$3
558803
650
0
$a
Social medicine.
$3
558786
650
0
$a
Public health.
$3
560998
700
1
$a
Nakamura, Yasuhide.
$e
author.
$4
aut
$4
http://id.loc.gov/vocabulary/relators/aut
$3
1324277
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer Nature eBook
776
0 8
$i
Printed edition:
$z
9789811520884
776
0 8
$i
Printed edition:
$z
9789811520907
776
0 8
$i
Printed edition:
$z
9789811520914
830
0
$a
Trust, Interdisciplinary Perspectives,
$x
2509-7679 ;
$v
2
$3
1306744
856
4 0
$u
https://doi.org/10.1007/978-981-15-2089-1
912
$a
ZDB-2-SLS
912
$a
ZDB-2-SXS
950
$a
Social Sciences (SpringerNature-41176)
950
$a
Social Sciences (R0) (SpringerNature-43726)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入